<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916173</url>
  </required_header>
  <id_info>
    <org_study_id>FM-ART</org_study_id>
    <nct_id>NCT02916173</nct_id>
  </id_info>
  <brief_title>Triggering of Follicular Maturation</brief_title>
  <official_title>Triggering of Follicular Maturation Using Human Chorionic Gonadotrophin With Gonadotrophin Releasing Hormone Agonist Versus Human Chorionic Gonadotrophin Alone in Antagonist Protocol in Assisted Reproductive Technology : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The follicular phase of the menstrual cycle involves the hourly release of
      gonadotropin-releasing hormone, which binds to receptors on the gonadotropes. This results in
      the secretion of follicle stimulating hormone and luteinizing hormone in hourly pulses that
      regulate follicular growth. At midcycle, rapidly rising estradiol from the dominant follicle
      and a small rise in progesterone lead to a gonadotrophic surge. An increase in the amplitude
      of Luteinizing hormone and Follicle stimulating hormone pulses initiates oocyte maturity and
      triggers ovulation approximately
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of M II oocytes in both groups</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate in each group</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate in each group</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Increase Pregnancy Rate</condition>
  <arm_group>
    <arm_group_label>Human chorionic gonadotrophin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Human chorionic gonadotrohpin injection 5000 unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human chorionic gonadotrophin + agonist group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Chorionic Gonadotrophin</intervention_name>
    <description>250 unit intramuscular</description>
    <arm_group_label>Human chorionic gonadotrophin group</arm_group_label>
    <other_name>Ovitrelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotrophin + gonadotrophin releasing hormone agonist</intervention_name>
    <description>250 unit intramuscular + 1 mg subcutaneous</description>
    <arm_group_label>Human chorionic gonadotrophin + agonist group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infertile couples wishing to do intracytoplasmic injection trial .

          2. first intracytoplasmic injection trial

          3. Body mass index:18-30.

        5-Antral follicular count: more than 5 follicles in one ovary 6-normal, mild or moderate
        male factor infertility. 7- Antimullerian hormone &gt;1 ng/ml

        Exclusion Criteria:

          1. Azoospermic male.

          2. Body mass index more than 29.

          3. Patients with endometriosis .

          4. Antimullerian hormone &lt; 1 ng/ml
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Abbas</name>
      <address>
        <city>Assiut</city>
        <state>Cairo</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

